Literature DB >> 9169439

Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3.

J Chung1, A G Gao, W A Frazier.   

Abstract

Integrin-associated protein (IAP or CD47) is a receptor for the cell/platelet-binding domain (CBD) of thrombospondin-1 (TS1), the most abundant protein of platelet alpha granules. Although it associates with alphaIIbbeta3, IAP has no known function in platelets. TS1, the CBD, and an IAP agonist peptide (4N1K) from the CBD of TS1 activate the platelet integrin alphaIIbbeta3, resulting in platelet spreading on immobilized fibrinogen, stimulation of platelet aggregation, and enhanced tyrosine phosphorylation of focal adhesion kinase. Furthermore, 4N1K peptide selectively stimulates the phosphorylation of LYN and SYK and their association with FAK. The phosphorylation of SYK is blocked by pertussis toxin, implicating a Gi-like heterotrimeric G protein. IAP solublized from membranes of unstimulated platelets binds specifically to an affinity column of 4N1K peptide. Both alphaIIb and beta3 integrin subunits and c-Src bind along with IAP. This complex of proteins is also detected with immunoprecipitation. Activation of platelets with the agonist peptide 4N1K results in the association of FAK with the IAP-alphaIIbbeta3 complex. Thus an important function of TS1 in platelets is that of a secreted costimulator of alphaIIbbeta3 whose unique properties result in its localization to the platelet surface and the fibrin clot.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169439     DOI: 10.1074/jbc.272.23.14740

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Thrombospondins as matricellular modulators of cell function.

Authors:  P Bornstein
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.

Authors:  Maria E Bamberger; Meera E Harris; Douglas R McDonald; Jens Husemann; Gary E Landreth
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

3.  Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42.

Authors:  Motoaki Miyashita; Hiroshi Ohnishi; Hideki Okazawa; Hiroyasu Tomonaga; Akiko Hayashi; Tetsuro-Takahiro Fujimoto; Nobuhiko Furuya; Takashi Matozaki
Journal:  Mol Biol Cell       Date:  2004-06-23       Impact factor: 4.138

Review 4.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

5.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

Review 6.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

7.  Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub)endothelial VWF from cleavage by ADAMTS13.

Authors:  Arnaud Bonnefoy; Kim Daenens; Hendrik B Feys; Rita De Vos; Petra Vandervoort; Jos Vermylen; Jack Lawler; Marc F Hoylaerts
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

8.  Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1.

Authors:  Cordula Klockenbusch; Juergen Kast
Journal:  J Biomed Biotechnol       Date:  2010-06-28

9.  Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation.

Authors:  Laura A Maile; Lee B Allen; Christopher F Hanzaker; Katherine A Gollahon; Paul Dunbar; David R Clemmons
Journal:  Exp Diabetes Res       Date:  2010-06-20

10.  CD47 regulates bone mass and tumor metastasis to bone.

Authors:  Ozge Uluçkan; Stephanie N Becker; Hongju Deng; Wei Zou; Julie L Prior; David Piwnica-Worms; William A Frazier; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.